Glenmark Pharma Launches Combination Drug For Type 2 Diabetic Patients

It is priced at Rs 14.90 per day, thereby reducing the daily cost of therapy by 40 per cent, making it more affordable to the masses, the company said in a statement

Topics

Glenmark Pharmaceuticals | Diabetes drug

Press Trust of India  |  New Delhi 



Glenmark Pharmaceuticals

It has been launched under the brand name Zita-PioMet, and contains Teneligliptin (20 mg), Pioglitazone (15 mg) and Metformin (500mg/1000mg) in a sustained release (SR) formulation.

').insertAfter(".article-content__img");$(".article-content__img div").find('div').remove();

Ltd on Wednesday said it has launched triple fixed-dose combination Teneligliptin with Pioglitazone and Metformin in India for diabetic patients.

This fixed-dose combination offers patients with Type 2 the convenience of once daily dosing to improve their glycemic control. It is priced at Rs 14.90 per day, thereby reducing the daily cost of therapy by 40 per cent, making it more affordable to the masses, the company said in a statement.

It has been launched under the brand name Zita-PioMet, and contains Teneligliptin (20 mg), Pioglitazone (15 mg) and Metformin (500mg/1000mg) in a sustained release (SR) formulation, it added.

"Type 2 patients in India often face issues of beta cell dysfunction along with insulin resistance. In fact, the prevalence of high insulin resistance in India is 38 per cent compared to the global incidence of 15 per cent," EVP & Business Head - India Formulations Alok Malik said.

The market for oral anti-diabetic drugs in India is estimated to be Rs 11,877 crore with an annual growth of 6.3 per cent against the corresponding period previous year, the company said citing IQVIA sales data for the 12-month period ended November 2022.

It further said as per the International Federation (IDF), the prevalence of diabetes in India is expected to increase to 125 million by 2045, 77 per cent of which would have uncontrolled diabetes.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)


Subscribe to Business Standard Premium

Exclusive Stories, Curated Newsletters, 26 years of Archives, E-paper, and more!

First Published: Wed, December 21 2022. 23:32 IST


RECENT NEWS

Titi Coles Legacy In Finance: Pioneering Diversity And Leadership

Titi Cole, one of the most senior Black women in the world of finance, recently exited her high-profile role at Citi. He... Read more

Rising Rates, Rising Challenges: Bankers Adapt To Serve Troubled Companies In A Changing Economic Landscape

As interest rates climb, troubled companies are facing heightened financial pressures, prompting them to seek assistance... Read more

The Elusive Nature Of Fraud Detection: Exploring The Auditor's Dilemma

In the intricate world of financial reporting, auditors serve as guardians of integrity, tasked with uncovering discrepa... Read more

The Battle For Depositors: US Lenders Ramp Up Efforts Amidst Rate Uncertainty

In the competitive landscape of the US banking sector, retaining depositors is paramount for lenders seeking to maintain... Read more

Beyond Capital: Unveiling The Complexities Of Bank Failure Prediction

In the realm of banking, the ability to predict and prevent failures is paramount for financial stability and consumer c... Read more

Central Banks And The Economic Horizon: Steering Through Uncertaintie

In the evolving landscape of global financial markets, the strategic role of central banks has come under intense scruti... Read more